RadNet (RDNT) Scheduled to Post Earnings on Wednesday

RadNet (NASDAQ:RDNT) is scheduled to release its earnings data before the market opens on Wednesday, February 14th. Analysts expect RadNet to post earnings of $0.11 per share for the quarter.

RadNet (NASDAQ:RDNT) last released its earnings results on Thursday, November 9th. The medical research company reported $0.12 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.12. The firm had revenue of $227.60 million during the quarter, compared to analysts’ expectations of $232.84 million. RadNet had a net margin of 1.21% and a return on equity of 23.73%. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 EPS. On average, analysts expect RadNet to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

RadNet (NASDAQ RDNT) opened at $9.95 on Wednesday. The company has a market cap of $473.86, a price-to-earnings ratio of 43.26, a P/E/G ratio of 2.19 and a beta of 0.67. RadNet has a one year low of $5.25 and a one year high of $11.90. The company has a debt-to-equity ratio of 7.88, a quick ratio of 1.29 and a current ratio of 1.29.

In other news, EVP Norman R. Hames sold 7,500 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $9.68, for a total value of $72,600.00. Following the completion of the transaction, the executive vice president now owns 397,587 shares in the company, valued at approximately $3,848,642.16. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director John V. Crues sold 20,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $10.08, for a total transaction of $201,600.00. Following the completion of the transaction, the director now owns 563,781 shares of the company’s stock, valued at approximately $5,682,912.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 133,084 shares of company stock valued at $1,321,587. Corporate insiders own 9.36% of the company’s stock.

Several research firms recently commented on RDNT. Zacks Investment Research cut shares of RadNet from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. TheStreet cut shares of RadNet from a “b-” rating to a “c” rating in a research note on Friday, October 27th. Finally, BidaskClub upgraded shares of RadNet from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th.

WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/07/radnet-rdnt-scheduled-to-post-earnings-on-wednesday.html.

RadNet Company Profile

RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.

Earnings History for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply